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Background Coronavirus disease 19 (COVID-19) is known to present with disease severities of varying
degree. In its most severe form, infection may lead to respiratory failure and multi-organ dysfunction.
Here we study the levels of extracellular histone H3 (H3), neutrophil elastase (NE) and cfDNA in relation to
other plasma parameters, including the immune modulators GAS6 and AXL, ICU scoring systems and
mortality in patients with severe COVID-19.
Methods We measured plasma H3, NE, cfDNA, GAS6 and AXL concentration in plasma of 83 COVID-19-
positive and 11 COVID-19-negative patients at admission to the Intensive Care Unit (ICU) at the Uppsala
University hospital, a tertiary hospital in Sweden and a total of 333 samples obtained from these patients
during the ICU-stay. We determined their correlation with disease severity, organ failure, mortality and
other blood parameters.
Results H3, NE, cfDNA, GAS6 and AXL were increased in plasma of COVID-19 patients compared to
controls. cfDNA and GAS6 decreased in time in in patients surviving to 30 days post ICU admission.
Plasma H3 was a common feature of COVID-19 patients, detected in 40% of the patients at ICU
admission. Although these measures were not predictive of the  nal outcome of the disease, they
correlated well with parameters of tissue damage (H3 and cfDNA) and neutrophil counts (NE). A subset
of samples displayed H3 processing, possibly due to proteolysis.
Conclusions Elevated H3 and cfDNA levels in COVID-19 patients illustrate the severity of the cellular
damage observed in critically ill COVID-19 patients. The increase in NE indicates the important role of
neutrophil response and the process of NETosis in the disease. GAS6 appears as part of an early
activated mechanism of response in Covid-19.
Background
In severe cases, COVID-19 disease develops into an acute respiratory distress syndrome (ARDS), an acute
lung injury causing patients to be dependent of ventilator support, which may be accompanied by
development of multiple organ failure (MOF) [1]. Mortality appears is seen primarily in patients over the
age of 65 [2–5] and is highest for infected individuals with underlying comorbidities such as
hypertension, cardiovascular disease or diabetes [6–8]. For patients who are taken into the intensive care
unit (ICU), a high SOFA score and increased levels of  brin D-dimers have been reported [9] to associate
with poor prognosis. Mild thrombocytopenia (platelet counts < 150 × 109 cells per L) can be found in 70–
95% of patients with severe COVID-19 [10, 11], but does not appear to be an important predictor of
disease progression or adverse outcome [11, 12]. However, 35–45% of COVID-19 patients develop
thromboembolic complications that contribute to the overall clinical prognosis [13], a much higher
proportion than the 5–15% usually seen in critically ill patients [14–16]. These coagulopathies include
thrombotic microangiopathies and disseminated intravascular coagulation (DIC). The observed
symptoms are reminiscent of bacterial sepsis but COVID-19 has distinct features [17] given the relatively
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mild reduction in platelet count and high values of D-dimer seen in COVID-19, pointing at a somewhat
different pathological mechanism. The involvement of immune regulatory and hemostatic pathways
appears evident.
Given the systemic infection and activation of the innate immune system in severe COVID-19 patients
and the organ injury, in particular in the lungs, cellular components released upon cellular disruption or
neutrophil activation may contribute to COVID-19 disease. This is in line with the observation that in the
acute respiratory distress syndrome, the involvement of the innate immune systems’ neutrophil
extracellular traps, NETs was previously shown to occur and to contribute to disease progress [18].
Extracellular histones are cytotoxic proteins that originate from the activation of neutrophils during
NETosis [19–21] or from damaged tissues [22], while cell free DNA (cfDNA) and the protease neutrophil
elastase (NE) are released concomitantly [23]. Histones and cfDNA, are known to activate Toll-like
receptors (TLRs) and promote proin ammatory cytokine release via receptor-dependent and independent
pathways [24, 25]. Extracellular histones and NE have antimicrobial activities and aid in the killing of
pathogens. However, while serving a protective function, NETs are potentially harmful to the host. NET
formation in lung tissue is able to disturb microcirculation and NETs can easily expand in pulmonary
alveoli,  lling the lungs [26], while it was seen that histones can rapidly and strongly accumulate in the
lung capillary network [27].
Histones have been shown to activate and recruit leukocytes [28], damage alveolar macrophages [29],
activate erythrocytes [30], epithelial and endothelial cells, in particular pulmonary endothelial cells [31–
33]. Collectively, extracellular histones cause an in ammatory response that leads to microvascular
leakage and endothelial dysfunction, inducing an immunothrombotic procoagulant condition and
eventually organ failure. If not cleared from circulation, histones as well as cfDNA facilitate severe
systemic in ammation and worsen the clinical condition [34, 35]. In a previous study [36] we reported a
correlation with mortality of the plasma concentration of extracellular histone H3 in sepsis patients
admitted to the ICU. Presence of NE in plasma is associated with exacerbations, lung function decline
and disease severity in patients with COPD, bronchiectasis and cystic  brosis [37–39] and decrease of NE
levels in bronchiectasis patients improved lung function and airway in ammation [40].
At the same time that it provides a  rst line of defense against infections, the innate immune system
initiates self-control responses to prevent damage to the host. One system involved in early
immunomodulation is the GAS6/TAM ligand/receptor system [41]. GAS6 is a vitamin K-dependent protein
that activates the TAM family (Tyro3, AXL and MerTK) of tyrosine kinase membrane receptors [42]. The
GAS6/TAM system regulates the immune response by modulating cytokine production, inducing a
regulatory cellular response pro le and by mediating efferocytosis, removing irreversibly damaged cells.
The system also provides a mechanism of regulating endothelial and platelet activation and interaction
[43].
Extracellular histones and cfDNA are implicated in regulation of in ammatory and hemostatic pathways
in the context of severe viral infections and ARDS, all of which are implicated in COVID-19. Therefore, the
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objective of this study was to determine circulating levels of extracellular histone H3, cfDNA, NE, and
components of the GAS6/TAM system in a group of 83 consecutive patients admitted to an intensive
care unit (ICU) and compare them with pre-COVID-19 UCI patients (n = 11) and healthy controls (n = 15).
Materials And Methods
Subjects and sampling
The study was approved by the Swedish National Ethical Review Agency (EPM; No. 2020 − 01623).
Informed consent was obtained from the patient, or next of kin if the patient was unable give consent.
The Declaration of Helsinki and its subsequent revisions were followed. The protocol of the study was
registered (ClinicalTrials ID: NCT04316884).
All adult patients with con rmed or suspected COVID-19 admitted to the ICU between March 21, and April
13, 2020 were screened for eligibility. The diagnosis was established by PCR detection of SARS-CoV-2 E
and N-genes in nasopharyngealswabs according to previously described protocols [44]. Plasma samples
were collected from 83 consecutive patients. We further used 11 previously included ICU-patients without
COVID-19 as ICU-controls and included 15 healthy control subjects who were healthy university employed
volunteers.
For a subset of patients, longitudinal plasma samples were available (n = 22), taken between days 1 and
12, which allowed analysis of time-dependent development of plasma values for the markers measured.
For other patients, longitudinal sampling could not be performed due to mortality and/or limitations in
logistic capacity at the peak of ICU occupancy.
The  rst blood sample (in citrate buffer) collected after a patient was admitted to the ICU was used as
baseline measurement. Platelet poor plasma (PPP) was prepared by centrifugation of the blood for
10 min at 3000 g at 4 ºC, after which the supernatant was carefully pipetted, whilst taking care not to
disturb the cell-containing lower layer by keeping a generous margin from the buffy coat. PPP was
aliquoted and snap-frozen until use. The healthy control PPP was prepared by the same method as the
patient plasma.
Quantitation of cell-free DNA
Cell-free DNA (cfDNA) was quantitated from plasma essentially as described earlier [45] using a real-time
PCR-based assay. In short, plasma samples were diluted 8-fold in water to result in a  nal assay dilution
of 40 times. Reactions were performed in 96-well plates (Roche) employing a LightCycler 480 qPCR
machine (Roche). Reaction volumes contained 5 µL of TATAA Probe GrandMaster Mix/no ROX (TATAA
Biocenter), 0.5 µL TATAA Alu-60 assay probes (TATAA Biocenter), 2.5 µL H2O and 2 µL of sample.
Ampli cation consisted of a pre-denaturation step 2 minutes at 95 °C, to activate the DNA Polymerase in
the master mix. Followed by 40 cycles of denaturation at 95 °C for 5 s, annealing at 60 °C for 10 s and
extension at 60 °C for 30 s. A calibration range (from 1 to 300 ng/µL) using puri ed and quantitated DNA
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standard prepared as described [46] was included in each analysis, facilitating the direct correlation of Ct
values to DNA concentration.
Quantitation of NE, sAXL, and GAS6 in Plasma
NE, soluble AXL (sAXL), and GAS6 levels in plasma were determined by the ELISA technique using
commercial kits from R&D systems (DuoSet ELISA, Bio-techne, Minneapolis, USA) according to the
manufacturer’s instructions. For determination of sAXL, the plasma form of the AXL cellular receptor, and
GAS6, plasma samples were diluted 1:40 and 1:200 for NE. All samples were determined in duplicates.
Analysis of extracellular histone H3
Extracellular histone H3 levels were determined using a semi-quantitative method previously described
[36, 47]. Brie y, plasma dilutions were subjected to SDS-PAGE gel electrophoresis and transferred to PVDF
membranes (Bio-Rad Laboratories, Hemel Hempstead, UK) using semi-dry blotting. Membranes were
blocked and incubated with primary anti-H3 antibody, o/n at 4 °C, (sc-8654-R, Santa Cruz Biotechnology,
Heidelberg, Germany), followed by a secondary biotin-conjugated IgG for 30 minutes at RT (ab97083,
Abcam, Cambridge, UK) and a streptavidin-biotin/alkaline phosphatase complex (Vectastain ABC-Alkaline
Phosphatase for 30 min at RT, Vector Laboratories, Burlingame, USA). Histone H3 bands were detected by
luminescent ECL substrate (Advansta, San Jose, USA). Resulting band densities were quanti ed by
ImageQuant TL software (GE Healtcare, Little Chalfont, UK), as compared to known concentrations of
puri ed calf thymus H3 (Roche, Basel, Switzerland). This analysis is independent of frequently observed
cross reactivity of histone antibodies with non-histone plasma proteins and allows the inspection of
potential in vivo histone proteolytic processing. The detection of citrullinated histone H3 was performed
on a subset of 50 randomly selected COVID-19 patients that had veri ed presence of H3 and used an
anti-citrulline antibody to inspect the presence of citrullinated protein at an overlaying position at 15 kDa
employing the anti-citrulline detection kit (Part number 17- 347B-1) and the monoclonal antibody
(MABS487, Merck) in combination with a polyclonal anti-human IgGHRP-labelled antibody (DAKO,
P0214). Imaging was performed as described for the histone H3 analysis described above.
Statistical analysis
Graphpad Prism version 8 (Graphpad Software Inc., La Jolla, CA, USA) and SPSS Statistics version 26
(SPSS Inc., Chicago, IL, USA) were used for statistical analysis. We employed a Kolmogorov-Smirnov test
to inspect normality of data. Parametric data are presented as mean (SD) or geometric mean (95% CI) for
log-transformed data unless stated. Non-parametric data are presented as median and inter quartile
range (IQR). We used paired and unpaired t-test and one-way analysis of variance (ANOVA) to compare
variables. Mann-Whitney tests were used for comparison of groups. *** indicates p < 0.001.
Results
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Of all ICU patients included, 83 patients had a con rmed COVID-19 diagnosis and 11 patients did not
have COVID-19 and were used as ICU control patients. We obtained a total of 315 plasma-samples from
the 83 patients with con rmed COVID-19, while 18 samples from 11 patients were obtained from the ICU
control group. The healthy control group consisted of 15 individuals with a median age of 32 (IQR 24–
37) of which 7 were male (47%).
The baseline (day 1) characteristics of the 83 ICU patients are shown in Table 1. Between the COVID-19
and the non-COVID-19 patients, males were overrepresented in the infected group, with 71.1% (p = 0.030),
whereas BMI was not different between both ICU groups. Non-COVID-19 patients tended to be older than
the COVID-19 patients. To allow comparison with a healthy population, a healthy control group was
further included in our analyses.
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Table 1
Demographic and baseline characteristics of 94 patients on admission to the
Intensive Care Unit. Values are represented as median (IQR) or n (%).The p-value is
calculated for continuous parameters with the Mann-Whitney U test, and for






Age, yrs, median 60 (52–71) 70 (59–75) 0.193
Gender, male N 59 (71) 5 (46) 0.030
BMI 28.8 (25.1–32.7) 27.7 (25.4–31.8) 0.829
Respiratory rate, breaths/min 27 (22–35) 15 (15–17) 0.001
Heart rate, beats/min 88 (77–100) 80 (72–92) 0.208
MAP, mmHg 90 (81–98) 80 (67–86) 0.004
Temperature, °C 38.0 (37.4–38.7) 36.4 (36.4–36.7) < 0.001
Diabetes, yes 22 (27) 2 (18) 0.552
Hypertension, yes 41 (50) 4 (36) 0.375
Heart failure, yes 3 (4) 1 (9) 0.398
Ischemic heart failure, yes 8 (10) 0 (0) 0.282
Vessel disease, yes 12 (15) 1 (9) 0.628
Malignancy, yes 4 (5) 11 (100) < 0.001
HIPEC surgery, yes 0 (0) 11 (100) < 0.001
Pulmonary disease, yes 21 (25) 1 (9) 0.233
Asthma 14 (17) 1 (9)  
COPD 6 (7)    
Sarcoidosis 1 (1)    
Smoker No 67 (80.7) 9 (81.8) 0.721
Yes 3 (3.6) 0 (0)  
Previous 10 (12.0) 2 (18.2)  
Unknown 3 (3.6)    
Steroid treatment, yes 9 (11) 1 (9) 0.850







Anticoagulant treatment, yes 16 (19) 5 (46) 0.050
SAPS-3 52 (47–58) 54 (49–58) 0.568
SOFA 6 (4–8) 6 (6–8) 0.980
 
Physiological characteristics are also shown in Table 1. Between the COVID-19 and the non-COVID-19
patients, signi cant differences were observed in their clinical parameters, with respiratory rate, mean
arterial pressure (MAP) and body temperature being higher in the COVID-19 group.
Prior to ICU admittance, malignancy, representing the main indication for ICU admission for HIPEC
surgery of the non-COVID-19 group and anticoagulant treatment were signi cantly higher in the control
ICU group (p < 0.001 and p 0.050 respectively). All patients in both patient groups required supplemental
inspired oxygen (Supplemental Table 1), but in the ICU control patients no high- ow nasal oxygen (HFNO)
or oxygen masks were required, yet the latter group received more vasoactive treatment. No signi cant
differences were present in antibiotic use. Supplementary Tables 2 and 3 presents routine parameters
measured for most COVID-19 patients at study inclusion. The PaO2/FiO2 ratio, a clinical indicator of
respiratory dysfunction, was on average 149 mmHg (IQR 123–186 mmHg) in the COVID-19 group.
Leukocytes were increased in the ICU control patients whereas erythrocytes and thrombocytes were
within reference range for both patient groups. A signi cant rise in CRP, IL-6 (n = 40), procalcitonin, and
lactate dehydrogenase (LDH) was seen in the COVID-19 patients, indicative of the ongoing in ammatory
response and tissue damage. All these measures had the lower interquartile range above the reference
range. D-dimer, indicative of  brinolytic activation, was also above the reference range, although in the 19
patients where aPTT was measured, the median value was prolonged but within reference range.
Detection of Histone H3, cfDNA and NE in plasma.
Plasma samples from the 94 ICU patients, were analyzed together with those of 15 healthy volunteers
(Fig. 1). In the majority of patients (67%), no extracellular H3 could be detected at ICU admission. As
compared with plasma samples of the ICU control patients however, the levels of extracellular histone H3
in the COVID-19 patients on day 1 were signi cantly higher (p = 0.047), as well as compared to the
healthy controls (p = 0.025; Fig. 1A), while there was no signi cant difference between the ICU control and
healthy control group (Table 2). The cfDNA values from both ICU groups differ greatly (p < 0.001), with the
COVID-19 group presenting 25-times higher levels than of the control group (Fig. 1B). The levels of cfDNA
did not differ between the ICU control and healthy control patients (Table 2). There was a highly
signi cant difference between both groups when NE was determined (p < 0.001; Fig. 1C) with NE being
virtually absent from the ICU control group and the healthy controls (Table 2).
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Table 2
Baseline ICU patients and healthy control plasma parameters expressed as median
(IQR).










































P-values were calculated with the Kruskal-Wallis test with Dunn’s post-hoc test.
 
Detection of GAS6 and sAXL in plasma.
In COVID-19 and non-COVID-19 ICU patients, the GAS6 concentration at study inclusion was 24.8 (18.1–
33.3) ng/mL and 12.1 (9.5–15.9) ng/mL respectively, indicating a signi cant difference between both
groups (p < 0.001; Fig. 2A, Table 2). The concentration of the healthy control group 14.4 (11.0–19.7)
ng/mL is signi cantly lower (p < 0.001) compared to the COVID-19 ICU group, while no difference is found
with the non-COVID-19 ICU group (Table 2).
The concentration of sAXL at inclusion between the ICU groups being 19.8 (14.6–26.1) ng/mL and 13.2
(11.3–17.6) ng/mL respectively, showed a signi cant increase (p < 0.001) of the COVID-19 group
compared to the non-COVID-19. The concentration of the healthy controls 17.3 (13.7–18.5) ng/mL was
lower than that of the COVID-19 group, though this difference was not signi cant.
Correlations between different plasma markers and laboratory parameters.
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Table 3
Correlations between various parameters measured at day 1.
  N Correlation P
H3 vs. cfDNA 83 0.367 0.001
H3 vs. sAXL 83 0.245 0.026
H3 vs. NE 83 0.391 < 0.001
cfDNA vs. Leukocytes 79 0.235 0.037
cfDNA vs. Platelets 79 0.236 0.036
cfDNA vs AST 67 0.262 0.032
cfDNA vs. LDH 64 0.506 < 0.001
sAXL vs. Troponin I 65 0.355 0.004
GAS6 vs. Procalcitonin 72 0.246 0.038
Correlations were calculated with the Spearman’s rank-order correlation test. Correlations were
considered signi cant if P < 0.05, only signi cant correlations are mentioned here.
 
The concentration of H3 correlated with cfDNA and NE concentrations at ICU admission in COVID-19
patients (Table 3). At this point, there was no signi cant correlation between cfDNA and NE
measurements. In contrast, LDH correlated very well with cfDNA (0.506; p < 0.001), which could indicate a
common origin in cellular damage. Remarkably, sAXL correlated signi cantly with the myocardial injury
biomarker troponin I in this cohort.
These correlations persisted when all subsequent sampling was included (supplementary Table 4). In
addition, other correlations with biochemical parameters indicating organ damage were observed,
including H3 and cfDNA with AST, LDH and procalcitonin (weaker for H3 in the latter case; p = 0.029).
Interestingly, cfDNA correlated also with D-dimer and CRP when all points were considered, indicators of
ongoing coagulation and  brinolysis. Although NE correlated strongly with H3 as was the case with the
initial values, NE did not correlate signi cantly with other tissue damage parameters, nor with cfDNA,
while it correlated signi cantly with leukocyte and neutrophil cell count, as well as procalcitonin and
GAS6 (Supplementary Table 4).
Prognosis and time-dependent parameter development in COVID-19.
At ICU admission, the value of SAPS-3 score (but not SOFA, supplementary Fig. 1) was signi cantly
higher in the group of COVID-19 patients that did not survive (n = 21) compared to those that survived (n 
= 62; supplementary Table 5). Non-survivors were older, hypertensive (86%), and had vessel or ischemic
heart failure more frequently than survivors. Accordingly, they were more frequently treated with
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anticoagulants and ACEi/ARB treatment. They also suffered more thromboembolisms during ICU stay.
From the biochemical measurements performed, non-survivors had higher markers of organ damage,
including AST, troponin I and procalcitonin (Supplementary Table 6). In those patients where IL-6 was
determined, mean IL-6 concentration in non-survivors (n = 10) was almost 3 times that of survivors (n = 
30). Although cfDNA, H3, NE, sAXL and GAS6 were all elevated in COVID-19 positive patients at
admission, none of these parameters was a good predictor of  nal outcome. Indeed, at ICU admission,
there was no correlation of any of these parameters with SAPS-3 or SOFA scores.
In 22 patients where several samples could be obtained during their ICU stay, we studied the time-
dependent development of the markers. We arbitrarily divided the results in an early sample (day 1–5)
and a late sample (day 6–12), using the mean value of the different samples obtained during each period
(supplementary Table 7). Platelet counts, in the normal range in the baseline measurements, increased
signi cantly in the late samples, as well as leukocytes (supplementary Table 7). Markers of tissue
damage also increased, including ALT and AST. There were no signi cant differences between early and
late values of histone H3, cfDNA or NE, although more samples were positive for H3 in the latter group.
No differences were observed for sAXL or GAS6. We furthermore inspected if the correlations observed in
the initial samples persisted over the early (day 1–5) and late phase of ICU stay for the 22 COVID-19
patients for which data were available over this complete period of time (Supplementary Table 8). We
observed that H3 correlated with cfDNA over both time periods and generally showed persistent
correlation with neutrophil counts. Strong correlations were seen between NE levels and neutrophils
(0,810 and 0,708 respectively for early and late phase).
Next, we divided the 22 patients according to their  nal outcome at 30 days (Fig. 3). Those individuals
that survived (n = 15) showed a 40% decrease in cfDNA concentration in the late plasma samples.
Further, in these patients GAS6 concentration decreased more than 30% in late samples. In contrast,
neither cfDNA nor GAS6 decreased in the group of non-survivors (n = 7), with their late values being very
similar to the early ones. The same trends were observed in H3 and NE measurements, although in these
cases, it did not reach signi cance. In addition, when regarding the NE concentrations, we found both in
the early phase, and in the late phase a signi cant difference between survivors and non-survivors.
Histone Analysis
Extracellular histone H3 was detected exclusively in samples originating from COVID-19 patients. At ICU
admission, 27 out of 83 COVID-19 positive patients (33%) had detectable histone H3 in plasma. When
considered the whole group of 315 samples obtained at different time points, histones were detected in
135 (43%) samples obtained from 83 patients.
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Table 4






Histone Cleavage 55 (40.7%) 0 (0%)  
Histone H3 (µg/ml) 0.59 (0.14–1.39) 0.00 (0.00–0.00) < 0.001
NE (ng/ml) 98.6 (60.0–159.0) 53.5 (19.6–109.6) < 0.001
cfDNA (ng/µl) 555.0 (321.9–829.6) 244.8 (137.7–429.1) < 0.001
Cleavage of Histone H3 and Plasma levels of Histone H3, NE and cfDNA in all samples of COVID-19
patients (n = 315), expressed as median (IQR). Samples are strati ed in two groups depending on
histone H3 presence. P-value is calculated with the Mann-Whitney U test; p < 0.05 is considered
signi cant.
 
Histone positive samples contained signi cantly higher NE and cfDNA than those in which no H3 was
detected (p < 0,001 and p < 0,001 respectively, Table 4), in line with the strong correlation between these
parameters (Table 3 and supplementary table 4). The presence of histone in COVID-19 patients appeared
not randomly divided over time (Fig. 3). Although no statistical signi cance was reached for comparison
between early and late survivors/non-survivors, the average histone levels in early survivors were higher
than in late survivors, whereas average histone H3 levels in early non-survivors were lower than in late
non-survivors.
In several COVID-19 patients, histone H3 showed an additional 13 kDa band on Western blot (Figs. 4A
and 4B). This was seen in 37% of histone H3 positive patients at day 1 and overall in 40,7% of all
samples tested. The origin of this band is most likely a proteolytic cleavage of the single 15 kDa band. In
one patient, only the lower weight band was seen (patient 47, day 7, Fig. 4A), suggesting full H3
proteolysis. In 5 patients, the proteolysis disappeared in samples collected after 6 days or later of ICU
stay.
In addition to presence of histones per se, we found that in a subset of 50 randomly selected COVID-19
patients with histone H3 in their plasma, the presence of citrullinated histone and found that 36 of these
(72%) were positive for citrullination (Fig. 4C).
Discussion
Our study broadly assessed a series of biomarkers re ecting the process of cellular damage and NETosis
as well as a mechanism of early response to damage, the GAS6/AXL pathway, in a group of severely ill
patients, consecutively admitted at an ICU during the present COVID-19 pandemic. A non-COVID-19 group
was included consisting of ICU patients suffering from malignancies requiring surgery (Supplementary
Table 1). PaO2/FiO2 ratios were clearly lower in the COVID-19 group, resulting in higher percentage of
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invasive respiration applied. Increased tissue damage, and particularly lung tissue damage, with more
pronounced in ammation, in combination with pulmonary thromboembolic disease could explain this
difference. This is underscored by increases in CRP, IL-6, D-dimer, LDH, procalcitonin, ASAT and increased
neutrophil counts at admission (Supplementary Table 2).
Levels of cfDNA, H3 and NE differed signi cantly already at admission to ICU care between the COVID-19
and non-COVID-19 groups. This is likely indicative of increased tissue damage and neutrophil activation
in this group. Given the equimolar presence of core histones H1, H2A, H2B, H3 and H4 in nucleosomes,
exposure of H3 to the extracellular milieu, is equally indicative for presence of the other core histones.
However, histones H3 and H4 have been found to be the most toxic [21, 48]. While cfDNA and NE levels
appeared to decrease over time, we noted that when analyzing the full collection of H3 measured, the
highest levels of histones were found for the days 4–8 and that this marker was on average less present
during the  rst days of ICU admission. Given the difference to NE and the at least partial NETosis origin
of H3 (as indicated by their citrullination) we hypothesize that a rapid clearance of histone H3 in the early
phase of ICU stay could explain the observed overall lower levels of circulating free histone H3. The
clearance of cytotoxic histones could represent a protective response that is brought about by uptake by
immune cells, binding to intact glycocalyx or binding to endothelium, platelets, or vesicles that originate
from these cells. Even though more data are required to support our hypothesis, the latter could contribute
to the observed reduction in platelet counts and, by virtue of their capacity to activate endothelium and
platelets, to the observed increase in thromboembolic events. Remarkably, we noted that in a sub-set of
plasma samples that contained H3, exclusively found in the COVID-19 group, H3 was proteolyzed.
Several proteases are known to process extracellular histones including NE. Partial processing of H3 by
NE was shown to occur during NET formation [49]. Given the observed correlation between H3 proteolysis
and NE levels, we conclude that in COVID-19 patients, extracellular histones are most likely processed by
NE. Of note, we realize the limitations of the semi-quantitative H3 assay used here, mostly being time-
intensive, however, unless truly speci c antibodies are available, proteolysis would be undetected using
commonly applied solid-phase based methods like ELISA.
We further found that in a subset of 50 histone H3 containing samples, histone H3 was citrullinated in 36
(72%), suggesting that histone exposure involves the activity of PAD4 as is the case during ROS-
independent NETosis. It is likely that the non-citrullinated H3 originates from damaged tissue or from
PAD4-independent NETosis pathways.
It has been suggested that cfDNA could serve as a surrogate marker for NETosis in critically ill
mechanically ventilated patients in whom NETs contribute to local alveolar in ammation [50]. However,
our data show that cfDNA correlated best with H3, while the correlation with NE was less strong. This
could indicate that NET formation could be better re ected by the release of neutrophil-speci c markers
such as NE, while H3 and cfDNA could relate to cellular damage in a broader sense. cfDNA is a DAMP
able to activate TLRs. The sustained increase in cfDNA observed in COVID-19 patients would propagate
in ammation through TLR activation. In this sense, it is important to stress that cfDNA decreased over
time in those patients that survived the infection, while those that did not survive maintained constantly
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high plasma cfDNA concentrations. Likewise, increased levels of NE are able to reduce the lung
permeability barrier function and induce release of pro-in ammatory cytokines, collectively inducing
emphysematous lesions.
We observed H3 positive samples levels at ICU admission, like we found earlier in a critically ill ICU
population of sepsis patients[36]. While this points at similar pathways being involved in disease onset
and progression, other reports [51] pointed out that COVID-19 clinical features are similar but different
from those seen in sepsis. The observed normal platelet counts found in most samples in this study,
irrespective of the phase of the disease or its outcome, further underscore this point. A possible early
onset of NETosis, with an associated rise in extracellular histones is supported by our observation that NE
levels were evident already from day 1 till day 12, implying neutrophil activation and NETosis,
accompanied by cfDNA also being present already at day 1.
The components of the GAS6/TAM system have been shown to increase in a diverse spectrum of
in ammatory conditions [52], including sepsis and septic shock; but also systemic in ammatory
response syndrome (SIRS) without infection [53]. In several studies, GAS6 concentration in plasma at IC
admission correlated with severity of organ damage, either in SOFA or with damage of speci c organs
[53–57]. This also the case in viral infections. Using a murine model of respiratory syncytial virus (RSV)
infection, Shibata et al [58] showed that GAS6 is expressed upon infection in lung alveoli, leading to
conversion of alveolar macrophages into M2-like cells. These studies illustrate the modulatory role of the
innate response provided by the GAS6/TAM system and suggest that the presence of these components
in plasma could be an early event in the orchestration of the immune response to viral infections.
In our COVID-19 cohort, GAS6 concentrations at ICU admission more than doubled those of non-COVID-
19 IC patients. Among plasma determinations that correlate with GAS6 are the interleukins IL-6 [53, 54]
and IL-8 [54]. GAS6, IL-6 and IL-8 concentrations are increased in septic patients who develop acute lung
injury (ALI; [53). Plasma GAS6 concentration was able to signi cantly discriminate patients that would
develop ALI in that cohort {Yeh, 2017 #63]. Also, non-survivors of sepsis in ICU tend to have initial higher
concentration of GAS6 and GAS6 could predict mortality with an AUC of 0.7 [54]. However, in our cohort,
no evident correlation with severity of the lung symptoms could be established, which could re ect a
speci c characteristic of SARS-CoV-2 interaction with the system.
In our study group, GAS6 concentration was maximal at IC admission, and was maintained high in non-
survivors. Ni et al have shown that recombinant GAS6 infusion improves the outcome of experimental
sepsis in mice, controlling multi-organ dysfunction [59]. One of the target cells of GAS6 in bacterial
infection is the vascular endothelium, that showed reduced LPS-induced permeability in the presence of
GAS6. Interestingly, GAS6 is also necessary to maintain the response of vascular endothelium during
in ammatory conditions, allowing endothelial cell interactions with platelets and leukocytes [43].
While the concentration of sAXL was found increased in sepsis cohorts [53, 54], the increase was not so
evident and did not signi cantly correlate with organ damage, similarly to our observation in COVID-19
patients. Soluble AXL is an ADAM-shed form of the receptor, found in plasma in a complex with GAS6
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[60]. The speci c increase of GAS6 over sAXL in COVID-19 could re ect a need of free, active GAS6 in this
condition. Interestingly, sAXL showed a correlation with troponin I. This re ects the observed correlation
of sAXL with parameters and progression of heart failure also observed in previous studies [61], and
could indicate a speci c implication of AXL in the cardiac damage observed in COVID-19. It is possible
that in the context of COVID-19, GAS6 could be acting through another TAM receptor in this context,
MerTK. MerTK inhibition increases the in ammatory cytokine storm in LPS-induced ALI [62], acting as a
tolerogenic receptor under in ammatory conditions [63]. However, it has to be noted that LPS and other
PAMPs drastically reduce MerTK expression [63].
Conclusion
We have shown the presence of extracellular histone H3 and cfDNA in the plasma of COVID-19 patients
to be signi cantly different from plasma of ICU patients who did not have COVID-19. Cytotoxic
extracellular histone H3 was found in 40% of COVID-19 patients, theoretically contributing to disease
progress, but not predicting  nal disease outcome. Histones were found to correlate with parameters for
tissue damage and with neutrophil counts, implying their partial origin from NETosis. This was supported
by the observation of cfDNA that showed a strong correlation with extracellular histone levels, suggesting
their possible use as proxy markers for the assessment of plasma histone levels. In COVID-19, an early
activation of the GAS6 immunomodulatory pathway takes place, re ected in a clear increase of the
plasma concentration of this vitamin K dependent protein.
Of the markers tested, development of neutrophil elastase proofed signi cantly different in COVID-19
survivors, as compared to non-survivors, with NE levels showing a decrease over time in survivors as
opposed to an increase in non-survivors, again supporting the important role that neutrophils play in this
disease. The involvement of NETosis and DAMPS in COVID-19 provides a possible rational basis for
treatment options that are able to target NETosis or its associated cytotoxic and pro-in ammatory
DAMPS in support of existing therapies in the ICU.
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Detection of plasma markers H3, cfDNA and NE. Plasma from COVID-19 ICU patients (n=83) and non-
COVID-19 ICU patients (n=11) was tested for the presence of extracellular histone H3 (A), cfDNA (B) and
neutrophil elastase (C) at ICU admission. P-values were calculated with the Kruskall-Wallis test with
Dunn’s post-hoc test. P-values were considered signi cant if p < 0.05, * 0.05, ** 0.01, *** 0.001
Figure 2
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Detection of plasma markers GAS6 and sAXL. Plasma from COVID-19 ICU patients (n=83) and non-
COVID-19 ICU patients (n=11) was tested for the presence of GAS6 (A), sAXL (B) at ICU admission. P-
values were calculated with the Kruskall-Wallis test with Dunn’s post-hoc test. P-value were considered
signi cant if p < 0.05, * 0.05, ** 0.01, *** 0.001.
Figure 3
Detection of plasma markers GAS6 and sAXL. Plasma from COVID-19 ICU patients (n=83) and non-
COVID-19 ICU patients (n=11) was tested for the presence of GAS6 (A), sAXL (B) at ICU admission. P-
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values were calculated with the Kruskall-Wallis test with Dunn’s post-hoc test. P-value were considered
signi cant if p < 0.05, * 0.05, ** 0.01, *** 0.001.
Figure 4
Western blot analysis of COVID-19 patient plasma. Plasma dilutions were run on SDS-PAGE and histone
H3 was detected using a primary anti-H3 antibody. Along with patient plasma, aliquots of puri ed human
histone H3 were run for comparison and quantitation by means of  uor imaging. Full length histone H3 is
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visible at 15 kDa and cleaved histone H3 at 12 kDa. Results are shown as a composite of different blots.
Multiple day follow-up examples are given for (A) COVID-19 survivors (B) COVID-19 non-survivors (C)
examples of the randomly selected H3 positive samples for citrullination analysis. *no histone H3
detected that day, #plasma samples not provided
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